Skip to main content
GXO $48.60 +0.49%
GXO logo

GXO · GXO Logistics, Inc.

Track GXO — free
$48.60 +0.24 (+0.49%) At close · Aug 14
Market Cap
$5.55B
Shares
114.68M
All earnings calls

Earnings call · FY2025 Q4

GXO Logistics, Inc. Q4 FY2025 Earnings Call

GXO Logistics, Inc. Q4 FY2025 Earnings Call

Concluded Feb 11, 2026 Audio replay
Feb 11, 2026 1:02:26 69 turns
Period
FY2025 Q4
Runtime
1:02:26
Sources
4 artifacts

Executive readout · one minute

What matters this quarter

GXO reported record Q4 and full-year 2025 revenue of $3.5 billion and $13.2 billion with full-year adjusted EBITDA of $881 million, and issued 2026 guidance calling for 4–5% organic revenue growth, adjusted EBITDA of $930–$970 million (up ~8% at midpoint), and 20% adjusted diluted EPS growth at the midpoint.

Organic growth acceleration 69 North America underrepresentation opportunity 40 Strategic verticals growth 35 Margin expansion 34 AI and automation leadership 30 Wincanton integration benefits 22

Management tone

Confident

Net tone +72 · low hedging

Grounding quotes
  • “we delivered record revenue of $3.5 billion and record adjusted EBITDA of $255 million”
  • “GXO delivered a strong finish to 2025, setting a solid foundation to accelerate organic growth and profitability in 2026 and beyond”
  • “at the midpoint shows accelerating organic growth, adjusted EBITDA margin expansion, and an increase of 20% adjusted diluted EPS growth at the midpoint”
  • “We have $774 million of expected incremental new business revenue already secured for 2026. This is an increase of over 20% compared to this time last year”

Forward guidance

4 guided metrics

Management's latest ranges and targets are included below.

Research coverage

4 live sources

Switch sources without leaving this page or losing your listening position.

Revenue · derived Q4 $3.51B +7.9% YoY
Net income · derived Q4 $43.00M -57% YoY

Research materials

Open the source you need; every reader stays inside this workspace.

Key takeaways

What improved, and what deserves a closer read.

Constructive signals

  • Record Q4 revenue of $3.5 billion (+7.9% YoY) and full-year revenue of $13.2 billion (+12.5% YoY) with organic growth in every region
  • Full-year adjusted EBITDA of $881 million versus $815 million in 2024; Q4 adjusted EBITDA rose to $255 million from $251 million
  • New business wins exceeded $1 billion for the third consecutive year, with $774 million of incremental 2026 new business revenue secured, up over 20% YoY
  • 2026 guidance at midpoint implies accelerating organic growth, ~8% adjusted EBITDA growth to ~$950 million, and 20% adjusted diluted EPS growth
  • Q4 free cash flow of $163 million, up from $127 million in Q4 2024
  • Life sciences pipeline more than tripled in the last twelve months following the NHS anchor win, with new additions including Siemens Healthineers and Fresenius

Risks & pressure points

  • Full-year net income fell to $36 million from $138 million in 2024 and full-year diluted EPS dropped to $0.28 from $1.12
  • Full-year cash flows from operations declined to $434 million from $549 million in 2024
  • Q4 net income of $43 million was down from $100 million in Q4 2024, with Q4 diluted EPS of $0.37 versus $0.83
  • Full-year adjusted diluted EPS of $2.51 was below the prior year's $2.80
  • Management noted guidance is inherently unpredictable and may be materially affected by FX, macro, consumer demand, labor, supply chain, and inflation
  • Leverage currently at 2.5x with stated intent to continue deleveraging, and M&A is not on the short-term agenda, limiting near-term inorganic growth optionality

Key moments

Jump directly to management's words in the synchronized transcript.

“We remain disciplined in our capital expenditure and working capital management, which allows us to continue to invest in our business with high returns. Our record operating return on capital remained consistently strong, driven by solid operating performance.” Baris Oran, CFO

Forward guidance

From the 8-K filed Feb 10, 2026.

Metric Guided
Organic revenue growth
2026
4% – 5%
Adjusted EBITDA
2026
$930M – $970M
Adjusted diluted EPS
2026
$2.85 – $3.15
Adjusted EBITDA to free cash flow conversion
2026
30% – 40%
Full-screen source Call document